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Introduction
DBreast cancer is the most common malignant disease in West-
ern women. Historically, breast cancer was perceived as a single 
disease with various clinicalpathological features, and therefore, 
“one drug fits all” approaches drove the treatment regimens. The 
advent of  genomics studies has led to a new paradigm in which 
breast cancer is heterogeneous consisting of  different diseases 
from the same organ site. For example, gene expression profil-
ing analysis revealed that estrogen receptor (ER)-positive and 
ERnegative breast cancer are two distinct diseases with different 
risk factors, clinical presentations, outcomes, and responses to 
systemic therapies [1]. Consequently, the new paradigm demands 
a personalized strategy in cancer medicine, in which the selection 
of  treatment regimens for each cancer patient will largely rely on 
assessment by predictive biomarkers and study of  the anatomical 
and pathological features of  the cancer.
Adjuvant chemotherapy is still the major therapeutic option used 
to reduce recurrence after surgery for advanced breast cancer cas-
es as well as some early-stage breast cancer cases. In this area, the 
assessment of  anatomical and pathological features of  cancer is 
the mainstream practice to determine whether a patient needs to 
undergo chemotherapy. However, this strategy did not correctly 
predict prognosis for a large number of  patients [2]. For example, 
a global survey estimated that out of  ~ 60% early-stage breast 
cancer patients treated with adjuvant chemotherapy, only less than 
15% ultimately derived benefit [3]. In other words, over 85% of  
these patients suffered from toxic side-effects associated with 
chemotherapy with limited benefit.  Therefore, the clinicalpatho-
logical-guided approach is not sufficient for implementation of   a 
personalized therapy; many overtreatment cases can be avoided if  
appropriate predictive biomarkers are available [4]. 
The personalized treatment of  breast cancer has made great pro-
gress with predictive biomarkers [5]. Some biomarkers have been 
established, including the use of  ER expressions to determine 
the benefit of  tamoxifen therapy, human epidermal growth fac-
tor receptor 2 (HER2) expressions for trastuzumab treatment, 
and mutation of  breast cancer susceptibility protein (BRCA) for 
inhibitors of  poly-ADP(ribose) polymerase (PARP). For exam-
ple, the adjuvant tamoxifen therapy has been well established to 
significantly reduce long-term risks of  breast cancer recurrence 
in ER-positive patients [6]. Meanwhile, the overexpressions of  
HER2 gene products occur in approximately 20 to 25% of  hu-
man breast cancers, and are associated with an aggressive behav-
ior in tumors [7]. The subsequent development of  trastuzumab 
has significantly reduced the rate of  recurrence by approximately 
50 percent, representing the largest benefit in early breast cancer 
to be reported since the introduction of  tamoxifen in ER-posi-
tive disease [8]. More recently, the utility of  PARP inhibitors was 
found from promising results in selected BRCA-mutated tumor 
cases including breast cancer [9], which might relate to the facts 
that the cancer cells in patients with BRCA mutations have an 
increased reliance on PARP to repair their DNA [10]. Although 
much safer than chemotherapy, the targeted therapies with com-
panion biomarkers still held some severe toxicity concerns, such 
as the increased cardiac safety concern in the trastuzumab treat-
ment [11], and overtreatment should be avoided.  
The development of  therapies to effectively treat the breast can-
cer patients with overexpression of  HER2 has greatly inspired 
cancer genomic studies [12]. An enormous number of  genomic 
biomarkers have been proposed for assessing tumor prognosis 
and predicting the sensitivity of  chemotherapy [13]. The “70-
gene signature” (MammaPrintTM, Agendia) and “21-gene recur-
rent score” (Oncotype DXTM, Genomic Health) were most widely 
accepted. The MammaPrint assay measures the expression of  70 
genes from fresh or frozen breast cancer tissues using DNA mi-
croarray data to calculate a prognostic score to stratify patients 
into “good” or “poor” prognosis groups. The patients with 
“good” prognosis are likely to have no recurrence in 5 years and 
thus should not take adjuvant chemotherapy. In 2007, the U.S. 
Food and Drug Administration (FDA) has cleared MammaPrint 
as a prognostic tool for the lymph node negative breast cancer pa-
tients of  under 61 years of  age, ER negative or positive, with tu-
mors of  5 cm or less. Additionally, retrospective studies revealed 
its sensitivity to predict responses to neoadjuvant chemotherapy 
in patients [14]. Currently, MammaPrint is supported by the level 
II evidence according to Tumor Marker Utility Grading System 
(TMUGS) devised by the American Society of  Clinical Oncol-
ogy (ASCO) panelists, suggesting its acceptance over the clinical-
pathological features. 
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Oncotype DX measures the expressions of  21 genes from forma-
lin-fixed paraffin-embedded tissues using multiple quantitative re-
verse-transcriptase polymerase chain reactions (qRT-PCR) to de-
rive Recurrence Score (RS). RS, ranging between 0 and 100, assess 
a likelihood of  breast cancer recurrence in 10 years. Patients with 
low-risk (RS lower than 18), intermediate-risk (RS between 18 and 
31), and high-risk (RS greater than 31) correspond to the 10-year 
relapse rate of  7%, 14%, and 30%, respectively. This assay has 
been extensively tested in samples from randomized clinical trials, 
by which it is demonstrated as an independent prognostic factor 
and a predictive biomarker to assess the likely benefit from certain 
types of  chemotherapy for patients with ER-positive, node-nega-
tive breast cancer treated with adjuvant tamoxifen. Supported by 
the level I, the strongest level of  evidence of  TMUGS, the On-
cotype DX assay has been widely used in clinical practices in the 
USA. It has been included in the major guidelines issued by the 
National Comprehensive Cancer Network and ASCO guidelines 
to be used as tumor markers in breast cancer for decision making, 
and is also recommended by the St. Gallen International Expert 
Consensus on the Primary Therapy of  Early Breast Cancer. 
The clinical application of  MammaPrint and Oncotype assays 
helps to distinguish good-prognosis from poor-prognosis can-
cers, which may limit the thousands of  cases of  breast cancer pa-
tients suffering from toxic side-effects of  chemotherapy while re-
ceiving little benefit [2]. However, there are still numerous claims 
in literature acclaiming the improved prognostic factors that have 
found limited utility for clinical application. The gap may be re-
lated to an unclear intended use of  the genomic biomarkers or the 
inappropriate experimental design during the development [15, 
16]. For example, Perou et al. [17] utilized a clustering analysis to 
discover that breast cancer is composed of  at least four molecu-
lar subtypes based on gene expression patterns, including luminal 
(i.e., luminal A and B), HER2-enriched, basal-like, and normal 
breast like. These breast cancer subtypes have now become part 
of  the standard terminology of  breast cancer [1]. However, the 
clinical utility of  the subtype classification as a molecular assay has 
been hindered for a long time by the fact that the genes and meth-
odology used to define these subtypes is unclear. Until recently, a 
50-gene signature was proposed for the standardization of  breast 
cancer subtyping [18].  
Despite the advances in genomic biomarkers, there is still a con-
cern of  overstating their utility for breast cancer management 
compared to their utility in other fields [19]. 
• Firstly, no sufficient published evidences demonstrates that 
these genomic biomarkers perform better than tumor mor-
phology and basic immunohistochemistry for classifying pa-
tients by recurrence outcomes, or for predicting chemother-
apy benefit [20]. A recent study indicated that an IHC4 (ER, 
PR, HER2, and Ki67) score measured from four standard 
immunohistochemistry markers can provide similar prognos-
tic accuracy as Oncotype DX [21]. 
• Secondly, a meta-analysis of  large cohorts of  breast cancers 
revealed that the gene signatures are predominately com-
posed of  the proliferation-related genes, and these prolifera-
tion-related components contribute most to predict progno-
sis [22]. However, the heavily weighted proliferation-related 
gene signatures only work for ER-positive cancer but not for 
ER-negative. In the ER-negative cancer the proliferation-
related genes usually have high expression. 
• Thirdly, these signatures can predict benefits for general mul-
tidrug chemotherapy regimens, but met challenges to opti-
mize “personalized” treatment predicting the response of  
specific chemotherapy agents [23]. 
• Fourthly, the patients with intermediate risk are still a huge 
challenge in decision-making using these genomic biomark-
ers. Several efforts have been initiated to assess the utility of  
genomic biomarkers for this category of  patients. For ex-
ample, a clinical trial called TAILORx was implemented to 
test patients with intermediate recurrence scores determined 
by Oncotype DX. Another clinical trial called MINDACT 
was also initiated to evaluate the patients with discordance 
assessed risk between AdjuvantOnline (a clinical tool for de-
cision-making in adjuvant chemotherapy) and MammaPrint. 
• Lastly, both Oncotype DX and MammaPrint cost over 
$4,000 for one test. Although they can be beneficial to pa-
tients by identifying good-prognosis from poor-prognosis 
cancers, the high cost still acts as a huge financial barrier for 
many patients. 
Though the initial claim that genomic biomarkers will replace 
the clinicalhistological approach seems to be over optimal, gene 
expression profiling analysis has undoubtedly made a significant 
impact on our understanding of  the biology of  breast cancer and 
helped thousands of  patients to spare unnecessary chemotherapy 
with improved life quality. The current genomic biomarkers pro-
vide limited benefit mainly due to their heavy reliance on pro-
liferation-related genes. However, they can be further improved 
through a better understanding of  the disease. For example, the 
genes related to other cancer mechanisms like invasive, metastasis, 
and immune response may be a better and more specific biomark-
er, particularly for the ER-negative breast cancer. Furthermore, 
microarrays that only measure the expression of  the pre-defined 
genes are the current mainstream technology used for the discov-
ery of  genomic biomarkers, whereas the newly emerging next-
generation sequencing technology provides a more sensitive and 
precise measurement of  the whole-transcriptome sequence [24], 
which will inevitably lead to the identification of  more predictive 
biomarkers and therapeutic targets. Notably, the Nature journal 
recently published a range of  studies to present whole genome 
analysis of  breast cancer and to provide a landscape of  the ge-
netic diversity in breast cancer, which vindicates refined tumor-
classification strategies and potential new therapeutic targets [12, 
25]. Besides the advances in technologies, the U.S. FDA and the 
National Institute of  Health have embraced personalized medi-
cine through adjusting the scientific and regulatory structure [5]. 
Very recently, a draft of  FDA guidance for industry entitled “in 
vitro companion diagnostic devices” was published for com-
ment, which emphasizes making personalized therapies feasible 
by identifying patients who can benefit (http://www.fda.gov/
medicaldevices/deviceregulationandguidance/guidancedocu-
ments/ucm262292.htm).  Therefore, it is expectant that genomics 
biomarkers will continue to help moving the treatment of  breast 
cancer toward personalized medicine.
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